Hannon Jason

The insider at CIK 0001330401 — a former NuVasive executive whose Form 4 profile now centers entirely on Orthofix Medical Inc. (OFIX) — carries a register whose defining feature is a seven-year, sell-free accumulation in OFIX totaling approximately 93,500 shares across acquisitions that blend mechanical RSU vesting with one open-market discretionary buy at $12.87 in June 2024, which is the register's most meaningful conviction signal. The OFIX build has been relentless and one-directional: annual or semi-annual RSU-vesting acquisitions from June 2020 through June 2026, with no disposals at any point. The open-market buy of 14,354 shares at$12.87 in June 2024 is a deliberate out-of-pocket purchase at a price near OFIX's post-restructuring trough — a signal that the insider, who knows the orthopedic-device company's business from the inside, was willing to commit personal capital when the stock was deeply out of favor. Meanwhile, the insider's prior NuVasive (NUVA) position — accumulated during years of executive service — was fully liquidated in September 2023 through nine simultaneous sell transactions totaling approximately 38,300 shares, an exit that coincides with the insider's transition from NuVasive to Orthofix's orbit. The register's current state: essentially 100% OFIX, no diversification, no sells, no hedging activity — the picture of an insider who has consolidated residual equity exposure into a single name they know well.